The neuroprotective potential of different cannabinoids and other modulators of the endocannabinoid system have been largely investigated in the last 15–20 years, mainly in preclinical models, in other chronic progressive neurodegenerative disorders (reviewed in [14, 22]), including TDP-43-based models of ALS [18, 19, 66], and also in Tau-dependent models of FTD [10, 25]. Here, MAPT is linked to amyotrophic lateral sclerosis.